Iradimed (IRMD) Financials

$53.47 +0.53 (+1.00%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$53.46 -0.02 (-0.03%)

As of 05/2/2025 04:05 PM Eastern

Annual Income Statements for Iradimed

This table shows Iradimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	13	17	19
Consolidated Net Income / (Loss)	13	17	19
Net Income / (Loss) Continuing Operations	13	17	19
Total Pre-Tax Income	16	22	24
Total Operating Income	16	20	22
Total Gross Profit	41	50	56
Total Revenue	53	66	73
Operating Revenue	53	66	73
Total Cost of Revenue	12	15	17
Operating Cost of Revenue	12	15	17
Total Operating Expenses	26	30	34
Selling, General & Admin Expense	11	15	16
Marketing Expense	13	12	16
Research & Development Expense	2.28	2.86	2.83
Total Other Income / (Expense), net	0.55	1.70	2.31
Other Income / (Expense), net	0.55	1.70	2.31
Income Tax Expense	3.35	4.55	5.04
Basic Earnings per Share	$1.02	$1.36	$1.52
Weighted Average Basic Shares Outstanding	12.56M	12.60M	12.67M
Diluted Earnings per Share	$1.02	$1.35	$1.50
Weighted Average Diluted Shares Outstanding	12.64M	12.72M	12.78M
Weighted Average Basic & Diluted Shares Outstanding	12.59M	12.66M	12.72M

This table shows Iradimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	3.43	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15
Consolidated Net Income / (Loss)	3.43	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15
Net Income / (Loss) Continuing Operations	3.43	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15
Total Pre-Tax Income	4.24	4.70	4.35	5.30	6.41	5.68	5.24	6.27	6.42	6.34
Total Operating Income	4.13	4.25	4.01	4.96	5.91	5.16	4.75	5.63	5.79	5.80
Total Gross Profit	11	11	12	12	13	13	13	14	14	15
Total Revenue	13	15	15	16	17	17	18	18	18	19
Operating Revenue	13	15	15	16	17	17	18	18	18	19
Total Cost of Revenue	2.86	3.64	3.75	3.94	3.67	4.04	4.21	3.92	4.13	4.63
Operating Cost of Revenue	2.86	3.64	3.75	3.94	3.67	4.04	4.21	3.92	4.13	4.63
Total Operating Expenses	6.41	6.97	7.71	7.22	6.93	8.25	8.64	8.38	8.40	8.96
Selling, General & Admin Expense	2.88	2.70	3.92	3.31	3.62	4.27	3.99	4.10	3.97	3.87
Marketing Expense	3.04	3.67	0.79	2.95	2.86	5.54	0.82	3.48	3.80	7.52
Research & Development Expense	0.49	0.60	3.00	0.96	0.45	-1.56	3.83	0.80	0.64	-2.44
Total Other Income / (Expense), net	0.11	0.45	0.34	0.34	0.50	0.52	0.50	0.64	0.63	0.54
Other Income / (Expense), net	0.11	0.45	0.34	0.34	0.50	0.52	0.50	0.64	0.63	0.54
Income Tax Expense	0.81	1.03	0.94	1.12	1.34	1.14	1.11	1.37	1.37	1.20
Basic Earnings per Share	$0.27	$0.29	$0.27	$0.33	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40
Weighted Average Basic Shares Outstanding	12.56M	12.56M	12.59M	12.60M	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M
Diluted Earnings per Share	$0.27	$0.29	$0.27	$0.33	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40
Weighted Average Diluted Shares Outstanding	12.63M	12.64M	12.69M	12.72M	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M
Weighted Average Basic & Diluted Shares Outstanding	12.57M	12.59M	12.59M	12.60M	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M

This table details how cash moves in and out of Iradimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-4.04	-8.20	2.47
Net Cash From Operating Activities	10	13	26
Net Cash From Continuing Operating Activities	10	13	26
Net Income / (Loss) Continuing Operations	13	17	19
Consolidated Net Income / (Loss)	13	17	19
Depreciation Expense	0.67	0.77	0.82
Non-Cash Adjustments To Reconcile Net Income	1.59	2.61	2.52
Changes in Operating Assets and Liabilities, net	-5.02	-7.11	3.05
Net Cash From Investing Activities	-1.37	-8.01	-8.82
Net Cash From Continuing Investing Activities	-1.37	-8.01	-8.82
Purchase of Property, Plant & Equipment	-1.87	-8.01	-8.82
Net Cash From Financing Activities	-13	-14	-14
Net Cash From Continuing Financing Activities	-13	-14	-14
Payment of Dividends	-13	-13	-14
Other Financing Activities, net	-0.15	-0.43	-0.66
Cash Income Taxes Paid	1.71	5.35	6.51

This table details how cash moves in and out of Iradimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	3.43	2.37	-15	3.05	0.92	3.02	-4.64	3.41	3.19	0.51
Net Cash From Operating Activities	3.94	3.04	4.65	3.51	1.39	3.91	3.88	6.64	9.12	5.99
Net Cash From Continuing Operating Activities	3.94	3.06	4.65	3.51	1.39	3.91	3.88	6.64	9.03	6.08
Net Income / (Loss) Continuing Operations	3.43	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15
Consolidated Net Income / (Loss)	3.43	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15
Depreciation Expense	0.44	-0.69	0.18	0.19	0.19	0.21	0.23	0.20	0.20	0.19
Non-Cash Adjustments To Reconcile Net Income	0.43	0.56	0.81	0.65	0.57	0.59	0.63	0.74	0.02	1.13
Changes in Operating Assets and Liabilities, net	-0.36	-0.48	0.25	-1.50	-4.43	-1.42	-1.11	0.80	3.75	-0.40
Net Cash From Investing Activities	-0.56	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06
Net Cash From Continuing Investing Activities	-0.56	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06
Purchase of Property, Plant & Equipment	-0.56	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06
Net Cash From Financing Activities	0.05	-0.20	-13	-0.09	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42
Net Cash From Continuing Financing Activities	0.05	-0.20	-13	-0.09	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42
Payment of Dividends	-	-	-13	-	-	-	-7.98	-1.90	-1.90	-1.90
Other Financing Activities, net	0.05	-0.20	-0.05	-0.09	-0.03	-0.26	-0.06	-0.06	-0.02	-0.52
Cash Income Taxes Paid	-	0.95	0.00	2.76	1.38	1.22	0.19	2.82	1.45	2.06

This table presents Iradimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	86	92	98
Total Current Assets	77	76	75
Cash & Equivalents	58	50	52
Accounts Receivable	13	12	11
Inventories, net	5.37	13	10
Prepaid Expenses	0.63	1.19	2.05
Plant, Property, & Equipment, net	2.40	9.29	17
Total Noncurrent Assets	5.62	6.87	6.27
Intangible Assets	2.07	2.52	3.10
Noncurrent Deferred & Refundable Income Taxes	0.70	2.12	2.82
Other Noncurrent Operating Assets	2.85	2.22	0.35
Total Liabilities & Shareholders' Equity	86	92	98
Total Liabilities	12	21	12
Total Current Liabilities	8.55	16	8.51
Accounts Payable	1.80	1.86	1.90
Accrued Expenses	0.09	0.12	0.12
Dividends Payable	0.00	7.98	0.00
Current Deferred Revenue	3.37	2.57	2.26
Current Deferred & Payable Income Tax Liabilities	0.00	0.25	0.00
Current Employee Benefit Liabilities	2.87	2.78	3.77
Other Taxes Payable	0.12	0.10	0.16
Other Current Liabilities	0.29	0.68	0.30
Total Noncurrent Liabilities	3.29	4.41	2.99
Noncurrent Deferred Revenue	1.38	2.79	2.99
Other Noncurrent Operating Liabilities	1.91	1.62	0.00
Total Equity & Noncontrolling Interests	74	71	87
Total Preferred & Common Equity	74	71	87
Total Common Equity	74	71	87
Common Stock	26	28	30
Retained Earnings	47	43	57

This table presents Iradimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	80	76	81	87	88	90	94
Total Current Assets	72	61	66	72	72	74	74
Cash & Equivalents	56	43	46	47	45	49	52
Accounts Receivable	11	12	11	13	13	12	10
Inventories, net	5.24	6.31	8.42	12	13	12	11
Prepaid Expenses	0.39	0.68	0.77	0.74	1.04	1.02	0.95
Plant, Property, & Equipment, net	2.29	8.64	8.72	8.89	9.45	10	14
Total Noncurrent Assets	5.38	5.68	6.62	6.59	6.68	5.90	5.80
Intangible Assets	1.88	2.21	2.35	2.46	2.67	2.75	2.89
Noncurrent Deferred & Refundable Income Taxes	0.99	0.62	1.77	1.80	1.88	2.59	2.46
Other Noncurrent Operating Assets	2.51	2.85	2.50	2.32	2.12	0.56	0.45
Total Liabilities & Shareholders' Equity	80	76	81	87	88	90	94
Total Liabilities	9.77	11	12	13	12	10	11
Total Current Liabilities	5.60	6.76	7.59	7.88	7.62	7.46	8.06
Accounts Payable	0.96	1.76	2.55	2.78	1.29	1.12	1.40
Accrued Expenses	0.10	0.10	0.11	0.11	0.12	0.12	0.12
Dividends Payable	-	-	-	-	0.00	0.00	0.00
Current Deferred Revenue	1.59	2.07	1.71	1.92	2.34	2.54	2.56
Current Deferred & Payable Income Tax Liabilities	-	0.49	-	-	0.93	0.00	0.00
Current Employee Benefit Liabilities	2.35	1.62	2.33	2.29	2.14	2.90	3.28
Other Taxes Payable	0.18	0.06	0.22	0.10	0.14	0.16	0.19
Other Current Liabilities	0.43	0.66	0.66	0.67	0.67	0.62	0.51
Total Noncurrent Liabilities	4.17	4.52	4.85	4.96	4.28	2.82	2.75
Noncurrent Deferred Revenue	2.18	2.59	3.01	3.23	2.76	2.82	2.75
Other Noncurrent Operating Liabilities	1.99	1.94	1.83	1.72	1.52	0.00	0.00
Total Equity & Noncontrolling Interests	70	64	69	75	76	80	83
Total Preferred & Common Equity	70	64	69	75	76	80	83
Total Common Equity	70	64	69	75	76	80	83
Common Stock	26	27	27	28	29	29	30
Retained Earnings	44	37	42	47	47	50	54

This table displays calculated financial ratios and metrics derived from Iradimed's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	27.48%	23.00%	11.71%
EBITDA Growth	49.88%	33.54%	11.51%
EBIT Growth	64.50%	34.35%	11.67%
NOPAT Growth	33.11%	27.89%	9.83%
Net Income Growth	37.56%	34.02%	11.87%
EPS Growth	37.84%	32.35%	11.11%
Operating Cash Flow Growth	-10.80%	34.08%	90.30%
Free Cash Flow Firm Growth	-29.77%	-69.70%	547.14%
Invested Capital Growth	62.44%	88.61%	16.71%
Revenue Q/Q Growth	5.94%	4.11%	2.72%
EBITDA Q/Q Growth	3.12%	9.10%	2.67%
EBIT Q/Q Growth	10.90%	4.71%	2.81%
NOPAT Q/Q Growth	-4.34%	5.33%	3.46%
Net Income Q/Q Growth	-1.68%	5.30%	3.26%
EPS Q/Q Growth	-1.92%	4.65%	3.45%
Operating Cash Flow Q/Q Growth	-3.16%	6.94%	8.81%
Free Cash Flow Firm Q/Q Growth	-13.57%	37.40%	-3.72%
Invested Capital Q/Q Growth	10.81%	6.51%	9.06%
Profitability Metrics	-	-	-
Gross Margin	77.45%	76.50%	76.94%
EBITDA Margin	31.61%	34.32%	34.26%
Operating Margin	29.32%	30.56%	29.99%
EBIT Margin	30.36%	33.16%	33.14%
Profit (Net Income) Margin	24.07%	26.22%	26.26%
Tax Burden Percent	79.28%	79.09%	79.23%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	20.72%	20.91%	20.77%
Return on Invested Capital (ROIC)	97.62%	69.89%	54.20%
ROIC Less NNEP Spread (ROIC-NNEP)	96.89%	67.19%	50.31%
Return on Net Nonoperating Assets (RNNOA)	-80.03%	-46.19%	-29.89%
Return on Equity (ROE)	17.59%	23.70%	24.31%
Cash Return on Invested Capital (CROIC)	50.03%	8.49%	38.78%
Operating Return on Assets (OROA)	19.22%	24.47%	25.49%
Return on Assets (ROA)	15.24%	19.35%	20.20%
Return on Common Equity (ROCE)	17.59%	23.70%	24.31%
Return on Equity Simple (ROE_SIMPLE)	17.41%	24.07%	22.15%
Net Operating Profit after Tax (NOPAT)	12	16	17
NOPAT Margin	23.24%	24.17%	23.76%
Net Nonoperating Expense Percent (NNEP)	0.73%	2.70%	3.89%
Return On Investment Capital (ROIC_SIMPLE)	-	22.19%	20.05%
Cost of Revenue to Revenue	22.55%	23.50%	23.06%
SG&A Expenses to Revenue	20.07%	23.07%	21.76%
R&D to Revenue	4.27%	4.36%	3.87%
Operating Expenses to Revenue	48.13%	45.95%	46.95%
Earnings before Interest and Taxes (EBIT)	16	22	24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	17	23	25
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.59	8.27	8.00
Price to Tangible Book Value (P/TBV)	4.72	8.58	8.30
Price to Revenue (P/Rev)	6.34	9.01	9.49
Price to Earnings (P/E)	26.33	34.37	36.13
Dividend Yield	3.72%	3.26%	1.70%
Earnings Yield	3.80%	2.91%	2.77%
Enterprise Value to Invested Capital (EV/IC)	17.81	18.26	18.58
Enterprise Value to Revenue (EV/Rev)	5.25	8.25	8.78
Enterprise Value to EBITDA (EV/EBITDA)	16.61	24.04	25.61
Enterprise Value to EBIT (EV/EBIT)	17.30	24.89	26.48
Enterprise Value to NOPAT (EV/NOPAT)	22.59	34.15	36.93
Enterprise Value to Operating Cash Flow (EV/OCF)	27.87	40.18	25.08
Enterprise Value to Free Cash Flow (EV/FCFF)	44.07	281.19	51.61
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.83	-0.69	-0.59
Leverage Ratio	1.15	1.22	1.20
Compound Leverage Factor	1.15	1.22	1.20
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	20.11	20.02	39.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.06	4.65	8.84
Quick Ratio	8.33	3.80	7.38
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	6.35	1.92	12
Operating Cash Flow to CapEx	535.61%	168.16%	290.63%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.63	0.74	0.77
Accounts Receivable Turnover	5.79	5.14	6.43
Inventory Turnover	2.49	1.69	1.45
Fixed Asset Turnover	23.85	11.22	5.61
Accounts Payable Turnover	9.31	8.43	9.00
Days Sales Outstanding (DSO)	63.04	70.98	56.76
Days Inventory Outstanding (DIO)	146.80	215.51	250.90
Days Payable Outstanding (DPO)	39.20	43.32	40.55
Cash Conversion Cycle (CCC)	170.63	243.17	267.11
Capital & Investment Metrics	-	-	-
Invested Capital	16	30	35
Invested Capital Turnover	4.20	2.89	2.28
Increase / (Decrease) in Invested Capital	6.04	14	4.95
Enterprise Value (EV)	280	541	643
Market Capitalization	338	591	695
Book Value per Share	$5.86	$5.67	$6.85
Tangible Book Value per Share	$5.70	$5.47	$6.61
Total Capital	74	71	87
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-58	-50	-52
Capital Expenditures (CapEx)	1.87	8.01	8.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	9.91	14
Debt-free Net Working Capital (DFNWC)	69	60	67
Net Working Capital (NWC)	69	60	67
Net Nonoperating Expense (NNE)	-0.44	-1.35	-1.83
Net Nonoperating Obligations (NNO)	-58	-42	-52
Total Depreciation and Amortization (D&A)	0.67	0.77	0.82
Debt-free, Cash-free Net Working Capital to Revenue	20.59%	15.12%	19.79%
Debt-free Net Working Capital to Revenue	129.33%	91.02%	91.11%
Net Working Capital to Revenue	129.33%	91.02%	91.11%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.02	$1.36	$1.52
Adjusted Weighted Average Basic Shares Outstanding	12.56M	12.60M	12.67M
Adjusted Diluted Earnings per Share	$1.02	$1.35	$1.50
Adjusted Weighted Average Diluted Shares Outstanding	12.64M	12.72M	12.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.59M	12.66M	12.72M
Normalized Net Operating Profit after Tax (NOPAT)	12	16	17
Normalized NOPAT Margin	23.24%	24.17%	23.76%
Pre Tax Income Margin	30.36%	33.16%	33.14%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	97.90%	76.91%	71.11%
Augmented Payout Ratio	97.90%	76.91%	71.11%

This table displays calculated financial ratios and metrics derived from Iradimed's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.92%	25.19%	25.70%	26.80%	23.10%	17.42%	13.72%	11.15%	11.04%	11.10%
EBITDA Growth	36.07%	14.59%	29.72%	17.37%	41.20%	46.78%	20.68%	17.91%	0.26%	11.08%
EBIT Growth	36.96%	51.07%	42.15%	26.77%	51.23%	20.79%	20.55%	18.32%	0.15%	11.66%
NOPAT Growth	30.02%	-14.54%	25.58%	21.18%	39.71%	24.09%	19.38%	12.36%	-2.46%	14.13%
Net Income Growth	33.03%	-5.63%	36.97%	28.97%	47.86%	23.58%	21.45%	17.26%	-0.35%	13.37%
EPS Growth	35.00%	-6.45%	35.00%	26.92%	48.15%	20.69%	18.52%	15.15%	0.00%	14.29%
Operating Cash Flow Growth	16.58%	-9.72%	225.77%	114.36%	-64.64%	28.75%	-16.42%	88.93%	554.54%	53.02%
Free Cash Flow Firm Growth	-144.41%	-175.03%	-637.03%	-221.50%	-296.70%	-260.61%	16.66%	35.47%	107.42%	97.49%
Invested Capital Growth	65.36%	62.44%	85.86%	68.66%	96.22%	88.61%	43.74%	34.35%	13.98%	16.71%
Revenue Q/Q Growth	5.39%	10.86%	4.11%	4.23%	2.32%	5.74%	0.84%	1.88%	2.21%	5.80%
EBITDA Q/Q Growth	-0.02%	-14.17%	13.00%	21.04%	20.28%	-10.78%	-7.09%	18.26%	2.28%	-1.16%
EBIT Q/Q Growth	1.38%	11.00%	-7.52%	21.81%	20.95%	-11.34%	-7.71%	19.56%	2.38%	-1.15%
NOPAT Q/Q Growth	3.44%	-0.59%	-5.55%	24.77%	19.26%	-11.71%	-9.14%	17.44%	3.53%	3.31%
Net Income Q/Q Growth	5.74%	7.19%	-7.28%	22.72%	21.23%	-10.41%	-8.88%	18.49%	3.03%	1.93%
EPS Q/Q Growth	3.85%	7.41%	-6.90%	22.22%	21.21%	-12.50%	-8.57%	18.75%	5.26%	0.00%
Operating Cash Flow Q/Q Growth	140.26%	-22.84%	52.89%	-24.37%	-60.36%	180.93%	-0.75%	70.96%	37.32%	-34.32%
Free Cash Flow Firm Q/Q Growth	-31.78%	-20.11%	-151.09%	19.11%	-62.60%	-9.19%	41.97%	37.36%	118.69%	-136.88%
Invested Capital Q/Q Growth	3.19%	10.81%	37.24%	7.48%	20.05%	6.51%	4.59%	0.46%	1.85%	9.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.63%	75.49%	75.74%	75.55%	77.78%	76.86%	76.07%	78.14%	77.44%	76.13%
EBITDA Margin	34.85%	26.98%	29.29%	34.01%	39.98%	33.73%	31.08%	36.08%	36.10%	33.73%
Operating Margin	30.82%	28.62%	25.89%	30.77%	35.78%	29.57%	26.98%	31.39%	31.59%	29.91%
EBIT Margin	31.61%	31.65%	28.11%	32.85%	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%
Profit (Net Income) Margin	25.56%	24.72%	22.01%	25.91%	30.70%	26.01%	23.51%	27.34%	27.55%	26.54%
Tax Burden Percent	80.88%	78.10%	78.31%	78.89%	79.07%	79.90%	78.89%	78.18%	78.67%	81.12%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	19.12%	21.90%	21.69%	21.11%	20.93%	20.10%	21.11%	21.82%	21.33%	18.88%
Return on Invested Capital (ROIC)	110.24%	93.87%	69.05%	78.74%	84.83%	68.31%	54.83%	62.78%	59.53%	55.36%
ROIC Less NNEP Spread (ROIC-NNEP)	110.09%	93.29%	68.48%	78.20%	84.06%	67.47%	53.94%	61.72%	58.53%	54.42%
Return on Net Nonoperating Assets (RNNOA)	-91.89%	-77.05%	-50.58%	-56.80%	-59.60%	-46.39%	-33.75%	-39.17%	-36.47%	-32.33%
Return on Equity (ROE)	18.34%	16.82%	18.47%	21.94%	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%
Cash Return on Invested Capital (CROIC)	64.58%	50.03%	18.52%	23.18%	6.67%	8.49%	26.72%	33.05%	43.45%	38.78%
Operating Return on Assets (OROA)	20.14%	20.03%	21.45%	25.03%	29.29%	24.03%	24.65%	28.35%	27.50%	25.16%
Return on Assets (ROA)	16.29%	15.65%	16.79%	19.75%	23.16%	19.20%	19.45%	22.17%	21.63%	20.41%
Return on Common Equity (ROCE)	18.34%	16.82%	18.47%	21.94%	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%
Return on Equity Simple (ROE_SIMPLE)	18.70%	0.00%	21.37%	21.29%	21.90%	0.00%	23.55%	23.40%	22.33%	0.00%
Net Operating Profit after Tax (NOPAT)	3.34	3.32	3.14	3.92	4.67	4.12	3.75	4.40	4.55	4.71
NOPAT Margin	24.93%	22.35%	20.28%	24.27%	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%
Net Nonoperating Expense Percent (NNEP)	0.15%	0.58%	0.57%	0.54%	0.78%	0.84%	0.89%	1.06%	1.01%	0.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	5.77%	-	-	-	5.42%
Cost of Revenue to Revenue	21.37%	24.51%	24.26%	24.45%	22.22%	23.14%	23.93%	21.86%	22.56%	23.87%
SG&A Expenses to Revenue	21.49%	18.14%	25.33%	20.54%	21.90%	24.49%	22.68%	22.90%	21.65%	19.98%
R&D to Revenue	3.67%	4.07%	19.39%	5.96%	2.74%	-8.91%	21.75%	4.47%	3.49%	-12.56%
Operating Expenses to Revenue	47.81%	46.87%	49.85%	44.78%	42.00%	47.29%	49.09%	46.75%	45.85%	46.21%
Earnings before Interest and Taxes (EBIT)	4.24	4.70	4.35	5.30	6.41	5.68	5.24	6.27	6.42	6.34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.67	4.01	4.53	5.49	6.60	5.89	5.47	6.47	6.62	6.54
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.14	4.59	7.54	8.53	7.34	8.27	7.27	6.96	7.64	8.00
Price to Tangible Book Value (P/TBV)	5.29	4.72	7.81	8.84	7.60	8.58	7.53	7.21	7.91	8.30
Price to Revenue (P/Rev)	7.13	6.34	8.60	9.84	8.70	9.01	8.17	7.98	8.94	9.49
Price to Earnings (P/E)	27.51	26.33	35.30	40.10	33.54	34.37	30.87	29.75	34.21	36.13
Dividend Yield	3.50%	3.72%	2.72%	2.25%	2.42%	3.26%	3.50%	1.44%	1.55%	1.70%
Earnings Yield	3.64%	3.80%	2.83%	2.49%	2.98%	2.91%	3.24%	3.36%	2.92%	2.77%
Enterprise Value to Invested Capital (EV/IC)	21.39	17.81	20.52	23.43	18.00	18.26	16.39	16.25	18.46	18.58
Enterprise Value to Revenue (EV/Rev)	6.03	5.25	7.84	9.07	7.95	8.25	7.51	7.28	8.21	8.78
Enterprise Value to EBITDA (EV/EBITDA)	18.56	16.61	24.74	29.04	24.28	24.04	21.68	20.72	23.95	25.61
Enterprise Value to EBIT (EV/EBIT)	20.79	17.30	25.33	29.21	24.13	24.89	22.45	21.44	24.79	26.48
Enterprise Value to NOPAT (EV/NOPAT)	23.42	22.59	33.96	39.60	33.30	34.15	30.88	29.88	34.80	36.93
Enterprise Value to Operating Cash Flow (EV/OCF)	29.25	27.87	33.37	35.88	39.78	40.18	40.00	31.97	24.86	25.08
Enterprise Value to Free Cash Flow (EV/FCFF)	41.28	44.07	144.13	126.94	357.68	281.19	72.36	56.38	45.27	51.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.83	-0.83	-0.74	-0.73	-0.71	-0.69	-0.63	-0.63	-0.62	-0.59
Leverage Ratio	1.15	1.15	1.17	1.17	1.16	1.22	1.17	1.15	1.15	1.20
Compound Leverage Factor	1.15	1.15	1.17	1.17	1.16	1.22	1.17	1.15	1.15	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	24.61	19.66	28.31	30.95	28.19	19.45	30.51	35.04	37.97	38.82
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.83	9.06	9.07	8.71	9.13	4.65	9.44	9.87	9.21	8.84
Quick Ratio	11.82	8.33	8.04	7.50	7.55	3.80	7.64	8.11	7.70	7.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.26	-2.72	-6.82	-5.52	-8.97	-9.80	-5.69	-3.56	0.67	-0.25
Operating Cash Flow to CapEx	708.12%	644.27%	70.86%	928.79%	317.22%	618.27%	811.01%	522.81%	227.24%	195.87%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.64	0.63	0.76	0.76	0.75	0.74	0.83	0.81	0.79	0.77
Accounts Receivable Turnover	6.75	5.79	6.26	6.15	5.37	5.14	5.51	6.03	6.16	6.43
Inventory Turnover	2.27	2.49	2.41	2.14	1.77	1.69	1.67	1.55	1.42	1.45
Fixed Asset Turnover	22.85	23.85	10.46	10.93	11.27	11.22	7.48	7.24	6.19	5.61
Accounts Payable Turnover	12.18	9.31	8.88	8.42	8.01	8.43	10.43	8.62	7.79	9.00
Days Sales Outstanding (DSO)	54.07	63.04	58.32	59.33	67.91	70.98	66.22	60.50	59.25	56.76
Days Inventory Outstanding (DIO)	160.54	146.80	151.44	170.51	205.64	215.51	218.72	236.09	256.56	250.90
Days Payable Outstanding (DPO)	29.98	39.20	41.11	43.35	45.57	43.32	35.00	42.33	46.83	40.55
Cash Conversion Cycle (CCC)	184.62	170.63	168.66	186.49	227.99	243.17	249.94	254.26	268.98	267.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	14	16	22	23	28	30	31	31	32	35
Invested Capital Turnover	4.42	4.20	3.41	3.24	3.00	2.89	2.58	2.56	2.40	2.28
Increase / (Decrease) in Invested Capital	5.60	6.04	9.96	9.43	14	14	9.43	7.96	3.89	4.95
Enterprise Value (EV)	303	280	443	543	501	541	508	506	585	643
Market Capitalization	359	338	485	589	548	591	553	555	637	695
Book Value per Share	$5.55	$5.86	$5.11	$5.48	$5.92	$5.67	$6.01	$6.29	$6.59	$6.85
Tangible Book Value per Share	$5.40	$5.70	$4.93	$5.29	$5.72	$5.47	$5.80	$6.07	$6.36	$6.61
Total Capital	70	74	64	69	75	71	76	80	83	87
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-56	-58	-43	-46	-47	-50	-45	-49	-52	-52
Capital Expenditures (CapEx)	0.56	0.47	6.56	0.38	0.44	0.63	0.48	1.27	4.01	3.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	11	12	13	17	9.91	19	18	15	14
Debt-free Net Working Capital (DFNWC)	66	69	55	59	64	60	64	66	66	67
Net Working Capital (NWC)	66	69	55	59	64	60	64	66	66	67
Net Nonoperating Expense (NNE)	-0.09	-0.35	-0.27	-0.26	-0.40	-0.42	-0.39	-0.50	-0.50	-0.44
Net Nonoperating Obligations (NNO)	-56	-58	-43	-46	-47	-42	-45	-49	-52	-52
Total Depreciation and Amortization (D&A)	0.44	-0.69	0.18	0.19	0.19	0.21	0.23	0.20	0.20	0.19
Debt-free, Cash-free Net Working Capital to Revenue	21.22%	20.59%	20.84%	21.18%	27.48%	15.12%	28.28%	25.31%	20.34%	19.79%
Debt-free Net Working Capital to Revenue	131.72%	129.33%	96.59%	97.71%	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%
Net Working Capital to Revenue	131.72%	129.33%	96.59%	97.71%	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.27	$0.29	$0.27	$0.33	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40
Adjusted Weighted Average Basic Shares Outstanding	12.56M	12.56M	12.59M	12.60M	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M
Adjusted Diluted Earnings per Share	$0.27	$0.29	$0.27	$0.33	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40
Adjusted Weighted Average Diluted Shares Outstanding	12.63M	12.64M	12.69M	12.72M	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.57M	12.59M	12.59M	12.60M	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M
Normalized Net Operating Profit after Tax (NOPAT)	3.34	3.32	3.14	3.92	4.67	4.12	3.75	4.40	4.55	4.71
Normalized NOPAT Margin	24.93%	22.35%	20.28%	24.27%	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%
Pre Tax Income Margin	31.61%	31.65%	28.11%	32.85%	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	96.26%	97.90%	96.18%	90.03%	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%
Augmented Payout Ratio	96.26%	97.90%	96.18%	90.03%	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%

Frequently Asked Questions About Iradimed's Financials

When does Iradimed's fiscal year end?

According to the most recent income statement we have on file, Iradimed's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Iradimed's net income changed over the last 2 years?

Iradimed's net income appears to be on an upward trend, with a most recent value of $19.23 million in 2024, rising from $12.83 million in 2022. The previous period was $17.19 million in 2023. See Iradimed's forecast for analyst expectations on what’s next for the company.

What is Iradimed's operating income?

Iradimed's total operating income in 2024 was $21.96 million, based on the following breakdown:

Total Gross Profit: $56.35 million
Total Operating Expenses: $34.39 million

How has Iradimed revenue changed over the last 2 years?

Over the last 2 years, Iradimed's total revenue changed from $53.30 million in 2022 to $73.24 million in 2024, a change of 37.4%.

How much debt does Iradimed have?

Iradimed's total liabilities were at $11.51 million at the end of 2024, a 44.5% decrease from 2023, and a 2.8% decrease since 2022.

How much cash does Iradimed have?

In the past 2 years, Iradimed's cash and equivalents has ranged from $49.76 million in 2023 to $57.96 million in 2022, and is currently $52.23 million as of their latest financial filing in 2024.

How has Iradimed's book value per share changed over the last 2 years?

Over the last 2 years, Iradimed's book value per share changed from 5.86 in 2022 to 6.85 in 2024, a change of 16.8%.

Related Companies

This page (NASDAQ:IRMD) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iradimed (IRMD) Financials

Frequently Asked Questions About Iradimed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iradimed (IRMD) Financials

Annual Income Statements for Iradimed

Quarterly Income Statements for Iradimed

Annual Cash Flow Statements for Iradimed

Quarterly Cash Flow Statements for Iradimed

Annual Balance Sheets for Iradimed

Quarterly Balance Sheets for Iradimed

Annual Metrics and Ratios for Iradimed

Quarterly Metrics and Ratios for Iradimed

Frequently Asked Questions About Iradimed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools